Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05640999 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
A Phase 2 study of Endometrial Cancer, sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 393
- Enrollment target
- 20
- Study locations
NCT05640999: Recruiting Phase 2 study of Endometrial Cancer, sponsored by Canadian Cancer Trials Group.
NCT05640999 is a Phase 2 study of Endometrial Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 393 participants, below the 522-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05640999, a Phase 2 study of Endometrial Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 393 participants
- Enrollment target
- 20
- Study locations
Study Summary
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / NSMP EC
Conditions Studied
Interventions
- OTHER Observation
- RADIATION Vaginal brachytherapy
- RADIATION Adjuvant radiotherapy (EBRT +/- brachytherapy)
Study Locations (20)
Florida
- University of Miami School of Medicine - Miami
- Sarasota Memorial Hospital - Venice - N. Venice
- Florida Cancer Specialists - Sarasota Downtown - Sarasota
- First Physicians Group-Sarasota - Sarasota
- Sarasota Memorial Hospital - Sarasota
- Sarasota Memorial Health Care Centre - Sarasota
- Florida Cancer Specialists - Venice Pinebrook - Venice
Georgia
- Grady Health System - Atlanta
- Emory University Hospital Midtown - Atlanta
- Piedmont Hospital - Atlanta
- Emory University Hospital Winship Cancer Institute - Atlanta
- Emory Saint Josephs Hospital - Atlanta
- Emory Decatur Hospital - Decatur
California
- Cedars-Sinai Medical Center - Los Angeles
- Huntington Memorial Hospital - Pasadena
- Sutter Medical Center Sacramento - Sacramento
Colorado
- UCHealth University of Colorado Hospital - Aurora
- AdventHealth Porter - Denver
Alaska
- Alaska Womens Cancer Care - Anchorage
Arizona
- University of Arizona Cancer Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 393 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
What NCT05640999 shows while recruiting
NCT05640999 is an interventional study that assigns participants to a tested intervention. The registered 393 participants enrollment target is mid-sized for trials with a published cap, below the 522-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Observation is the first listed.
NCT05640999 names 20 study sites across 6 states, led by Florida, Georgia, California.
Frequently Asked Questions
What is clinical trial NCT05640999 about?
NCT05640999 is a clinical study titled "Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER". This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / N...
What is the current status of trial NCT05640999?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 393 participants. The study started on 2022-12-19. Estimated completion is 2029-06-30.
What conditions does trial NCT05640999 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT05640999?
The interventions under investigation include: Observation (OTHER), Vaginal brachytherapy (RADIATION), Adjuvant radiotherapy (EBRT +/- brachytherapy) (RADIATION).
Who is sponsoring clinical trial NCT05640999?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05640999 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05640999's enrollment target sits among peer trials
393 41st of 181 higher than 141 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06613698 · 393 participants · Phase 2
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease
- NCT06657924 · 394 participants · Phase 2
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
- NCT07225660 · 394 participants · NA
Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI